CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a potent and selective inhibitor of cathepsin B, demonstrating an inhibition constant (Ki) of 2–5 nM and high selectivity over cathepsins H and L (Ki = 40–200 µM) [Product Page]. Chemical inhibition of cathepsin B with CA-074 protects cells from MLKL polymerization-induced necroptosis, a form of programmed cell death driven by lysosomal membrane permeabilization (LMP) and cathepsin B release (Liu et al., 2024). In vivo, CA-074 reduces bone metastasis in a 4T1.2 breast cancer mouse model without affecting primary tumor size [Product Data]. It modulates immune responses by promoting Th-1 polarization and reducing IgE/IgG1 production [Related Article]. CA-074 is soluble in multiple solvents and shows low cytotoxicity at up to 10 mM in cell culture.

Biological Rationale

Cathepsin B is a cysteine protease abundantly present in lysosomes. It is involved in protein turnover, antigen processing, and cell death pathways. In pathological conditions such as cancer, cathepsin B contributes to extracellular matrix degradation, tumor invasion, and metastasis (Liu et al., 2024). During necroptosis, MLKL polymerization induces lysosomal membrane permeabilization, resulting in the cytosolic release of active cathepsin B, which cleaves essential cellular proteins and promotes cell death. Inhibiting cathepsin B with small molecules like CA-074 can therefore modulate cell survival, inflammation, and metastatic processes [Strategic Dissection]. Research leveraging CA-074 has illuminated the role of cathepsin B in cancer progression and neurotoxic cascades, offering avenues for translational intervention.

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a small molecule that acts as a competitive, irreversible inhibitor of cathepsin B. It binds covalently to the active site cysteine residue of cathepsin B, blocking substrate access and enzymatic activity. CA-074 exhibits nanomolar potency (Ki = 2–5 nM) and is more than 10,000-fold selective for cathepsin B over cathepsins H and L (Ki = 40–200 µM) under standard in vitro assay conditions (pH 5.5, 25°C) [CA-074, Cathepsin B inhibitor]. Upon cellular stress or necroptotic signaling, MLKL polymers trigger lysosomal leakage, releasing active cathepsin B into the cytoplasm. CA-074, by inhibiting cathepsin B, interrupts this proteolytic cascade, preventing downstream protein cleavage and cell death (Liu et al., 2024). This mechanism underpins CA-074’s utility in dissecting cathepsin B–mediated pathways in cancer, neurodegeneration, and immune modulation.

Evidence & Benchmarks

• CA-074 inhibits cathepsin B activity with a Ki of 2–5 nM, showing >10,000-fold selectivity over cathepsins H and L (Ki = 40–200 µM) (https://www.apexbt.com/ca-074.html).
• Chemical inhibition or knockdown of cathepsin B protects cells from MLKL-mediated necroptosis in human colon cancer HT-29 cells (https://doi.org/10.1038/s41418-023-01237-7).
• In a 4T1.2 breast cancer mouse model, intraperitoneal injection of CA-074 at 50 mg/kg reduced bone metastasis without affecting the size of the primary tumor (https://www.apexbt.com/ca-074.html).
• CA-074 reduces neurotoxicity in primary neurons exposed to Abeta42-activated microglial cells (https://asc-j9.com/index.php?g=Wap&m=Article&a=detail&id=14830).
• CA-074 shifts immune response from Th-2 to Th-1, lowering IgE and IgG1 serum levels in mouse models (https://baxinhibitor.com/index.php?g=Wap&m=Article&a=detail&id=10877).
• CA-074 shows negligible cytotoxicity in cell culture at concentrations up to 10 mM (https://www.apexbt.com/ca-074.html).

Applications, Limits & Misconceptions

CA-074 is widely used as a selective probe for cathepsin B function in cancer metastasis, neurotoxicity, and immune modulation research. Its high selectivity allows precise dissection of cathepsin B–mediated proteolytic pathways. In vivo, CA-074 has demonstrated efficacy in reducing cancer bone metastasis and modulating immune responses. In vitro, it is effective in elucidating roles of cathepsin B in necroptosis and lysosomal membrane permeabilization [Next-Generation Inhibition], extending findings from earlier mechanistic studies. This article clarifies the translational significance of MLKL–cathepsin B axis inhibition, building upon and updating the context presented in ‘Strategic Dissection of Cathepsin B Pathways’ by focusing on validated in vivo outcomes and immune modulation.

Common Pitfalls or Misconceptions

• CA-074 does not inhibit cathepsin D or other non-cysteine lysosomal proteases; its selectivity is limited to cathepsin B (https://www.apexbt.com/ca-074.html).
• CA-074 is not effective against cathepsin B already covalently inactivated or denatured; it requires active site integrity (https://baxinhibitor.com/index.php?g=Wap&m=Article&a=detail&id=10877).
• The compound’s in vivo efficacy is demonstrated for metastasis reduction but not for shrinking established primary tumors (https://www.apexbt.com/ca-074.html).
• CA-074’s solubility in water requires ultrasonic assistance and may not be suitable for all aqueous formulations (https://www.apexbt.com/ca-074.html).
• Prolonged storage of CA-074 solutions is not recommended; activity loss may occur (https://www.apexbt.com/ca-074.html).

Workflow Integration & Parameters

CA-074 (SKU: A1926) is supplied as a solid and is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL, ultrasonic assistance). For in vitro assays, CA-074 is typically used at concentrations ranging from 100 nM to 10 µM, depending on assay sensitivity and cellular context. In vivo, dosing at 50 mg/kg by intraperitoneal injection in mice has been validated for metastasis studies. Solutions should be prepared fresh or stored short-term at -20°C to preserve activity. Cytotoxicity is negligible up to 10 mM in cell culture, supporting its use in mechanistic studies [the A1926 kit]. For immune modulation studies, monitoring of cytokine and immunoglobulin profiles is recommended to capture Th-1/Th-2 shifts. Detailed guidance for experimental design and troubleshooting is provided in ‘Redefining Translational Paradigms’, which this article extends by specifying validated solvent conditions and cytotoxicity data.

Conclusion & Outlook

CA-074 is a benchmark selective cathepsin B inhibitor with robust applications in cancer metastasis, neurotoxicity reduction, and immune response modulation. Its nanomolar potency and high selectivity enable mechanistic dissection of cathepsin B–mediated processes, particularly in the context of MLKL-driven necroptosis and lysosomal membrane permeabilization. Continuing advances in cathepsin B biology will further refine the use of CA-074 as both a research probe and a translational tool. For the latest protocols and validated use cases, consult the CA-074, Cathepsin B inhibitor product page and recent peer-reviewed studies.